Coherus Oncology (CHRS) Other Gross PP&E Adjustments (2016 - 2024)
Historic Other Gross PP&E Adjustments for Coherus Oncology (CHRS) over the last 12 years, with Q4 2024 value amounting to -$7.5 million.
- Coherus Oncology's Other Gross PP&E Adjustments rose 2858.64% to -$7.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$7.5 million, marking a year-over-year increase of 2858.64%. This contributed to the annual value of -$7.5 million for FY2024, which is 2858.64% up from last year.
- Per Coherus Oncology's latest filing, its Other Gross PP&E Adjustments stood at -$7.5 million for Q4 2024, which was up 2858.64% from $23.5 million recorded in Q3 2024.
- In the past 5 years, Coherus Oncology's Other Gross PP&E Adjustments registered a high of $28.9 million during Q3 2022, and its lowest value of -$14.1 million during Q4 2021.
- For the 5-year period, Coherus Oncology's Other Gross PP&E Adjustments averaged around $15.2 million, with its median value being $23.6 million (2024).
- Data for Coherus Oncology's Other Gross PP&E Adjustments shows a peak YoY increase of 7166.45% (in 2021) and a maximum YoY decrease of 4411.61% (in 2021) over the last 5 years.
- Over the past 5 years, Coherus Oncology's Other Gross PP&E Adjustments (Quarter) stood at -$9.8 million in 2020, then crashed by 44.12% to -$14.1 million in 2021, then surged by 33.74% to -$9.3 million in 2022, then decreased by 12.55% to -$10.5 million in 2023, then rose by 28.59% to -$7.5 million in 2024.
- Its Other Gross PP&E Adjustments stands at -$7.5 million for Q4 2024, versus $23.5 million for Q3 2024 and $23.7 million for Q2 2024.